

510(k) Submissions Workshop

AdvaMed Office 1301 Pennsylvania Ave. N.W. Suite 400 Washington, D.C. February 3 – 4, 2025

Feb 3, 2025

8:30 – 9:00 am Registration Check-In and Continental Breakfast

9:00 – 9:05 am Welcome and Introductions

9:05 - 10:30 am The Law and Regulations

Sally Maher, Regulatory Consultant, Sally Maher Consulting

510(k) definition

510 and 513 FDCA

• Guidance for 510(k): general & product specific

How to find it

o How to use it

Different types of 510(k)s; which to use

Review of bundling 510(k)s

FDA Product Codes – Activity

10:30 - 10:45 am Break

10:45 am - 12:00 pm 510(k) Strategy and Planning

Tony Blank, Senior Director of Regulatory Affairs, AtriCure

- Staff involved
- Role of each function
- RA responsibilities
- Use of guidance
- Global considerations
- Pre-submissions
- Predicates
- Breakthrough Devices Program
- Safer Technologies Program

12:00 – 1:00 pm Networking Lunch

1:00 – 2:15 pm Preparing the Submission

Jemin Jay Dedania, Director of Regulatory Affairs, Global Regulatory, Hogan Lovells Melissa Hall, Founder and Principal Consultant, Statera Regulatory Consulting

- · General information including how to select a predicate device
- Assembling the 510(k)
- eSTAR

Important Notice

The information provided in this course represents the personal opinions of the instructors and does not necessarily represent the opinions of AdvaMed staff. Companies relying on the information do so at their own risk and assume the risk of any subsequent liability that results from relying on the information. The information does not constitute legal advice.



2:15 - 2:30 pm Break

2:30 – 3:15 pm The FDA Review Process

Angela DeMarco, Biomedical Engineer, Center for Devices and Radiological Health, FDA

- How it works at FDA
- FDA/industry interactions
- Refuse to Accept
- Submission Issue meetings
- FDA holds
- Interactive review
- Least Burdensome flag
- Current pilots

3:15 – 3:30 pm Break

3:30 – 4:00 pm CDRH Ombudsman's Office

Ken Skodacek, Center for Devices and Radiological Health, Deputy Ombudsman, FDA

- Roles & Responsibilities
- Appeals Process

Feb 4, 2025

8:30 – 9:00 am Continental Breakfast

9:00 – 10:15 am Clearance: Launch and After

Tony Blank, Senior Director of Regulatory Affairs, AtriCure

- What clearance does and does not mean
- Promotional practices for 510(k) devices
 - o FDA
 - o FTC
- Complaint Handling and MDRs
- When to File a New 510(k) for Device Modifications
- Catch-up 510(k)s

10:15 - 10:30 am Break

10:30 - 11:00 am De Novo

Elaine Tseng, Counsel, King & Spaulding

- Definition of a De Novo
- Final Rule on De Novo
- When De Novo is used
- Differentiation from 510(k)

Important Notice

The information provided in this course represents the personal opinions of the instructors and does not necessarily represent the opinions of AdvaMed staff. Companies relying on the information do so at their own risk and assume the risk of any subsequent liability that results from relying on the information. The information does not constitute legal advice.



11:00 - 11:30 am

Regulatory Strategy for De Novo

Ginny Hu, Director, Regulatory Affairs, Dexcom

- Key eligibility criteria
- Benefit-risk analysis

11:30 am - 12:00 pm

Preparing the De Novo Submission

Bryan Osborne, Senior Director, Regulatory Affairs, Dexcom

- Content
- Assembling the submission

12:00 - 1:00 pm

Networking Lunch

1:00 - 1:30 pm

FDA Review Process for De Novo

Pooja Panigrahi, Policy Analyst, FDA

Peter Yang, De Novo Program Lead, Office of Regulatory Programs, Office of Product Evaluation, Center for Devices and Radiological Health, FDA

- Use of Pre-Submission meeting
- Rationale for De Novo
- Clinical Protocols
- Special Controls
- Benefit-Risk Considerations

1:30 - 2:00 pm

Maintenance of a Granted De Novo

Peter Yang, De Novo Program Lead, Office of Regulatory Programs, Office of Product Evaluation, Center for Devices and Radiological Health, FDA

- Post-market requirements
- Classification Order
- De Novo database, granting order, decision summary
- Use as a predicate
- Making changes to granted De Novo device

2:00 - 2:15 pm

Break

2:15 - 4:15 pm

Applied Learning and Breakout Discussions

* In person participants, only

- 510(k) & De Novo Recap
- Facilitated Breakout Group Deep Dive Hypothetical Case Studies & Key Takeaways
- Regroup for Q&A

4:15 pm

Adjournment

Important Notice

The information provided in this course represents the personal opinions of the instructors and does not necessarily represent the opinions of AdvaMed staff. Companies relying on the information do so at their own risk and assume the risk of any subsequent liability that results from relying on the information. The information does not constitute legal advice.